8-K: Bausch + Lomb Upsizes Senior Secured Notes and Loan Facilities for Debt Refinancing

Bausch + Lomb Corporation, a subsidiary of Bausch Health Companies Inc., announced the pricing of an upsized $675 million senior secured notes offering and increased new term B loan facility to $2.325 billion, aimed at refinancing existing debt.

Summary

• Bausch + Lomb Corporation, a subsidiary of Bausch Health Companies Inc., priced an offering of $675 million aggregate principal amount of senior secured floating rate notes due 2031.
• The notes offering size was increased from the previously announced $600 million.
• The notes will be sold to investors at a price of 99.500% of the principal amount.
• Bausch + Lomb is also seeking to partially refinance its credit agreement, intending to obtain a new $2.325 billion Term B Loan Facility and a new $800 million Revolving Credit Facility.
• The allocated size of the New Term B Loan Facility was increased from the previously announced $2.2 billion.
• The New Term B Loan is expected to accrue interest at a rate of Term SOFR + 4.25% per annum.
• Net proceeds from the notes offering and the New Term B Loan Facility will be used to repay outstanding borrowings under the existing revolving credit facility, refinance outstanding term A loans due 2027, and term B loans due 2027, and cover related fees and expenses.
• The closing of the notes offering is not contingent upon the closing of the New Term B Loan Facility or the New Revolving Credit Facility.
• The notes will be secured on a first priority basis by liens on the same assets that secure obligations under the company's credit agreement and 8.375% senior secured notes due 2028.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the successful upsizing of both the notes offering and the term loan facility, indicating strong market reception for Bausch + Lomb's debt. The refinancing strategy aims to improve the debt maturity profile. However, the forward-looking statements include a disclaimer about the uncertainty of closing the new loan facilities, which slightly tempers the overall positive outlook.

Positives

• Successful upsizing of the senior secured notes offering from $600 million to $675 million, indicating strong market demand.
• Increased allocation for the New Term B Loan Facility from $2.2 billion to $2.325 billion, suggesting favorable lender interest.
• The refinancing strategy aims to repay existing revolving credit and refinance term A and term B loans due 2027, which could improve the company's debt maturity profile.
• The closing of the Notes offering is not contingent on the New Term B Loan Facility or New Revolving Credit Facility, providing more certainty for the notes transaction.

Negatives

• The notes are being sold at a discount (99.500% of principal amount).
• The New Term B Loan is expected to accrue interest at Term SOFR + 4.25% per annum, which represents a cost to the company.

Risks

• There can be no assurances that Bausch + Lomb will be able to complete the New Term B Loan Facility and/or New Revolving Credit Facility transactions on the terms described or at all.
• The Notes have not been and will not be registered under the Securities Act or any state securities laws, limiting their sale to qualified institutional buyers and non-U.S. persons under specific exemptions.
• The Notes have not been and will not be qualified for sale to the public by prospectus under applicable Canadian securities laws, restricting their offer and sale in Canada to prospectus-exempt bases.

Future Outlook

Bausch + Lomb expects to complete the $675 million senior secured notes offering and secure new $2.325 billion Term B Loan and $800 million Revolving Credit Facilities by June 26, 2025. These transactions are intended to fully repay outstanding borrowings under its existing revolving credit facility and refinance its outstanding term A and term B loans due 2027, improving its debt maturity profile. However, there are no assurances that the loan facilities will close on the described terms or at all.

Management Comments

• Management announced the successful pricing of an upsized senior secured notes offering.
• Management indicated the company's intent to obtain new Term B Loan and Revolving Credit Facilities to refinance existing debt.
• Management stated that the net proceeds from the notes and new term loan will be used to repay existing revolving credit and refinance term A and term B loans due 2027.

Industry Context

This announcement reflects a common corporate finance strategy where companies with significant debt loads seek to optimize their capital structure by refinancing existing obligations. For a global eye health company like Bausch + Lomb, managing debt effectively is crucial for funding ongoing research and development, manufacturing, and commercial operations in a competitive market. The successful upsizing of the offering suggests favorable conditions in the debt capital markets for established healthcare companies.

Stakeholder Impact

• Shareholders: Potential positive impact due to improved debt maturity profile and potentially optimized interest costs, reducing financial risk.
• Creditors: Existing creditors will be repaid, while new noteholders and lenders will have secured positions.
• Employees/Customers/Suppliers: Indirect positive impact from a more stable financial position, allowing the company to continue operations and investments.

Next Steps

• Closing of the $675 million senior secured notes offering, expected on June 26, 2025.
• Closing of the $2.325 billion New Term B Loan Facility, expected on June 26, 2025.
• Closing of the $800 million New Revolving Credit Facility, expected on June 26, 2025.
• Use of net proceeds to repay outstanding borrowings under existing revolving credit facility.
• Use of net proceeds to refinance outstanding term A loans due 2027 and term B loans due 2027.

Key Dates

Keywords

Bausch + Lomb, Bausch Health Companies, Senior Secured Notes, Debt Refinancing, Term Loan, Revolving Credit Facility, SEC Filing, Form 8-K, Corporate Finance, Capital Markets, Pharmaceuticals, Eye Health